Sundar Jagannath

Sundar Jagannath Shares Long-Term CARTITUDE-1 Results on CAR T-Cell Therapy for Multiple Myeloma – Mount Sinai Department of Medicine

Mount Sinai Department of Medicine shared on LinkedIn:

“Sundar Jagannath shares long-term results from the CARTITUDE-1 study, demonstrating the potential for durable remission and improved survival in patients with relapsed or refractory multiple myeloma receiving CAR T-cell therapy.”

Read more.

An impactful insight about Multiple Myeloma.

Sundar Jagannath

cancer Mount Sinai Department of Medicine multiple myeloma OncoDaily Oncology Sundar Jagannath